Integra Lifesciences Holdings Corp (NASDAQ:IART) has been given an average recommendation of “Buy” by the fourteen brokerages that are currently covering the company, ARN reports. Four equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $72.33.
Several equities analysts recently commented on IART shares. Bank of America raised shares of Integra Lifesciences Holdings Corp from a “neutral” rating to a “buy” rating and upped their price target for the stock from $72.00 to $79.00 in a research report on Monday, September 21st. Zacks Investment Research upgraded shares of Integra Lifesciences Holdings Corp from a “sell” rating to a “hold” rating in a research note on Monday, September 14th. Piper Jaffray reiterated a “buy” rating on shares of Integra Lifesciences Holdings Corp in a research note on Thursday, September 3rd. Lake Street Capital decreased their price objective on shares of Integra Lifesciences Holdings Corp from $65.00 to $55.00 and set a “hold” rating for the company in a research note on Wednesday, August 26th. Finally, TheStreet downgraded shares of Integra Lifesciences Holdings Corp from a “buy” rating to a “hold” rating in a research note on Tuesday, November 3rd.
Shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) traded up 0.18% during midday trading on Tuesday, hitting $67.26. 132,341 shares of the stock were exchanged. Integra Lifesciences Holdings Corp has a 12-month low of $47.80 and a 12-month high of $68.46. The firm’s market cap is $2.49 billion. The firm has a 50 day moving average of $63.74 and a 200 day moving average of $62.19. 